RxDoctor Payments Data

Rakesh Sheliya, MD

Internal Medicine · Cary, NCNPI 1356652416

Payments from drug & device makers

$2,294in general payments, 2019–2025

Across 30 payments — averaging $76.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$521
  • Boehringer Ingelheim$422
  • AstraZeneca$277
  • AbbVie$228
  • Johnson & Johnson$227
  • Otsuka America Pharmaceutical, Inc.$120
  • plus $498 from 8 others

What the payments were for

  • Food & beverage$2,294100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,294 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$166,556
Medicare patients
387
Services billed
1,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin35$44,962
FarxigaDapagliflozin Propanediol30$43,951
AuryxiaFerric Citrate13$22,612
TradjentaLinagliptin14$7,690
Sevelamer Carbonate13$2,103
Hydralazine Hcl47$930
Bumetanide32$647
Calcitriol35$615
Amlodipine Besylate66$541
Ipratropium Bromide23$528
Losartan Potassium73$498
Furosemide83$483
Tamsulosin Hcl31$415
Isosorbide Mononitrate ErIsosorbide Mononitrate37$372
Glipizide ErGlipizide16$331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$422$52,65249 claims
AstraZenecaFarxiga$277$43,95130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →